Signatope develops protein biomarker assays using mass spectrometry-based immunoassays. It develops protein assays that are capable of detecting and quantifying biomarkers for organ damage and drug interactions in blood, urine, and tissue. It offers analytical services for clients in the pharmaceutical and chemical industries. It was founded in 2016 and is based in Reutlingen, Germany.
Latest Signatope News
Sep 25, 2018
Premium NEW YORK (GenomeWeb) – Protein analytics firm Signatope is applying its amino acid motif-specific antibody technology to identifying and measuring protein biomarkers for drug development. Get the full story with GenomeWeb Premium
Signatope Frequently Asked Questions (FAQ)
When was Signatope founded?
Signatope was founded in 2016.
Where is Signatope's headquarters?
Signatope's headquarters is located at Markwiesenstr. 55, Reutlingen.
What is Signatope's latest funding round?
Signatope's latest funding round is Seed VC.
How much did Signatope raise?
Signatope raised a total of $670K.
Who are the investors of Signatope?
Investors of Signatope include High-Tech Grunderfonds.